Subscribe Become an Author Add Company Sign Up Log In



Private company

We apply our novel AI based platform to small molecule chemical design challenges to increase speed and success while reducing the cost

Private company
United States of America based
$17.400 M
Research papers
Business model
  • Operations Service
  • Own Drug Discovery Programs
Therapeutic focus
  • Cardiovascular
  • Neuroscience
  • Oncology
Product type
  • Small molecules
Research focus
  • Preclinical Development

Investing history

2014Series B8.2
2009Series B5.5
2008Series A1.1
2008Series A2.6

Press releases

    No mentions found

Posts Mentioning This Company

New Tools, Products and Technologies
Biopharma Insights
Biopharma Insights
White Papers And Industry Reports


Artificial intelligence (AI) for drug discovery

Cloud-based computation for drug discovery projects using AI

Our platform offers cloud-scale artificial intelligence support for every design decision at each stage of drug discovery. Computational contract research …

Read more


No services posted yet

Clinical Trials

    No clinical trials found

  • WO2018049328 (from 2018-03-15), Bicyclic compounds useful as gpr120 modulators
  • WO2018049324 (from 2018-03-15), Monocyclic compounds useful as gpr120 modulators
  • WO2012078519 (from 2012-06-14), 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
  • WO2011031740 (from 2011-03-17), Antibacterial fluoroquinolone analogs
  • WO2011031743 (from 2011-03-17), Antibacterial fluoroquinolone analogs
  • WO2011031744 (from 2011-03-17), Antibacterial fluoroquinolone analogs
  • WO2011031745 (from 2011-03-17), Antibacterial fluoroquinolone analogs
  • WO2009137130 (from 2009-11-12), Antibacterial fluoroquinolone analogs
  • WO2007051065 (from 2007-05-03), Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
  • WO2006065950 (from 2006-06-22), Modeling biological effects of molecules using molecular property models
  • WO2006028524 (from 2006-03-16), Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
  • WO02059755 (from 2002-08-01), Rdx enhancement of system and method for implementing reusable data markup language (rdl)
  • WO0072197 (from 2000-11-30), Reusable data markup language
  • WO0161568 (from 2001-08-23), Rdl search engine
Publications (PubMed)
  • 31000801 (from 2019-04-20), Opportunities and challenges using artificial intelligence in ADME/Tox.
  • 29863875 (from 2018-06-05), Geometric Deep Learning Autonomously Learns Chemical Features That Outperform Those Engineered by Domain Experts.
  • 31080887 (from 2018-01-01), Wanted: Class VI Antiarrhythmic Drug Action; New Start for a Rational Drug Therapy.
  • 26020786 (from 2015-05-29), Summary of the DREAM8 Parameter Estimation Challenge: Toward Parameter Identification for Whole-Cell Models.
  • 22560567 (from 2012-05-09), Discovery of XL413, a potent and selective CDC7 inhibitor.
  • 19685583 (from 2009-08-18), Building today's platform company.

Assets (therapeutic products)

    No assets found

Year Partner Focus Amount of Deal

(2011, Jan. 1)
Boehringer Ingelheim Pharmaceuticals -- --

(2012, Jan. 1)
Merck -- --

(2017, Jan. 1)
Takeda -- --

(2019, Jan. 1)
Lundbeck Pharmaceuticals Identification of clinical candidates for the treatment of disorders in the central nervous system, including depression, psychosis, seizure and neurodegenerative disorders. --